The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients

European Urology

Volumn 71, Issue 4, 2017, Pages 680-687

  Del Re, Marzia ^a   Biasco, Elisa ^a   Crucitta, Stefania ^a   Derosa, Lisa ^a,c   Rofi, Eleonora ^a   Orlandini, Cinzia ^a   Miccoli, Mario ^a   Galli, Luca ^a   Falcone, Alfredo ^a   Jenster, Guido W ^b   van Schaik, Ron H ^b   Danesi, Romano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

AR V7; Digital droplet PCR; Exosomes; Hormonal therapy; Pharmacogenetics; Prostate cancer; Resistance

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR SPLICE VARIANT 7; BIOLOGICAL MARKER; ENZALUTAMIDE; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ISOPROTEIN; PHENYLTHIOHYDANTOIN; RNA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL PRACTICE; DISEASE ASSOCIATION; EXOSOME; FOLLOW UP; HUMAN; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RNA EXTRACTION; RNA ISOLATION; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; BLOOD; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SECONDARY; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROSTENES; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; RNA;

EID: 84994424610     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.08.012     Document Type: Article

References (18)

1. [1] Antonarakis, E.S., Lu, C., Wang, H., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 (2014), 1028–1038.
2. [2] Mateo, J., Carreira, S., Sandhu, S., et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373 (2015), 1697–1708.
3. [3] Crawford, E.D., Ventii, K., Shore, N.D., New biomarkers in prostate cancer. Oncology (Williston Park) 28 (2014), 135–142.
4. [4] Antonarakis, E.S., Lu, C., Luber, B., et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 1 (2015), 582–591.
5. [5] Dehm, S.M., Tindall, D.J., Alternatively spliced androgen receptor variants. Endocr Relat Cancer 18 (2011), R183–R196.
6. [6] Hu, R., Dunn, T.A., Wei, S., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69 (2009), 16–22.
7. [7] Welti, J., Rodrigues, D.N., Sharp, A., et al. Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer. Eur Urol 70 (2016), 599–608.
8. [8] Onstenk, W., Sieuwerts, A.M., Kraan, J., et al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol 68 (2015), 939–945.
9. [9] Takeuchi, T., Okuno, Y., Hattori-Kato, M., Zaitsu, M., Mikami, K., Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer. Res Rep Urol 8 (2016), 21–25.
10. [10] Hessvik, N.P., Phuyal, S., Brech, A., Sandvig, K., Llorente, A., Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim Biophys Acta 1819 (2012), 1154–1163.
11. [11] Junker, K., Heinzelmann, J., Beckham, C., Ochiya, T., Jenster, G., Extracellular vesicles and their role in urologic malignancies. Eur Urol 70 (2016), 323–331.
12. [12] Cai, X., Janku, F., Zhan, Q., Fan, J.B., Accessing genetic information with liquid biopsies. Trends Genet 31 (2015), 564–575.
13. [13] Gold, B., Cankovic, M., Furtado, L.V., Meier, F., Gocke, C.D., Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility?. A report of the association for molecular pathology. J Mol Diagn 17 (2015), 209–224.
14. [14] Kalluri, R., The biology and function of exosomes in cancer. J Clin Invest 126 (2016), 1208–1215.
15. [15] Wicha, M.S., Hayes, D.F., Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol 29 (2011), 1508–1511.
16. [16] Li, Y., Alsagabi, M., Fan, D., Bova, G.S., Tewfik, A.H., Dehm, S.M., Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 71 (2011), 2108–2117.
17. [17] Lu, C., Luo, J., Decoding the androgen receptor splice variants. Transl Androl Urol 2 (2013), 178–186.
18. [18] Scher, H.I., Lu, D., Schreiber, N.A., et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2 (2016), 1441–1449.